Foghorn Therapeutics Inc.
FHTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822462
No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Foghorn Therapeutics Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 61 | 59 | −2 |
| Shares | 26.2M | 26.8M | +544.6K (+2.1%) |
| Value | $162.8M | $188.4M | +$25.7M (+15.8%) |
New holders (8)
Institutions that held Foghorn Therapeutics Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 279,155 | $1.97M | 0.01% |
| Wade G W & Inc | 107,770 | $759.0K | 0.03% |
| Exchange Traded Concepts, LLC | 16,471 | $116.0K | 0.00% |
| Ikarian Capital, LLC | 15,000 | $105.6K | 0.04% |
| MetLife Investment Management | 11,445 | $80.6K | 0.00% |
| Alliancebernstein L.P. | 10,060 | $70.8K | 0.00% |
| Metropolitan Life Insurance Co | 1,295 | $9.12K | 0.00% |
| VisionPoint Advisory Group, LLC | 210 | $1.48K | 0.00% |
Sold out (10)
Institutions that held Foghorn Therapeutics Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Citadel Advisors LLC | 153,072 | $949.0K |
| Affinity Asset Advisors, LLC | 136,771 | $848.0K |
| Millennium Management LLC | 37,885 | $235.0K |
| Man Group plc | – | $210.7K |
| Russell Investments Group, Ltd. | 30,017 | $186.1K |
| Acadian Asset Management LLC | 27,085 | $165.0K |
| Tiaa, FSB | 14,469 | $89.7K |
| Trexquant Investment LP | 14,283 | $88.6K |
| NewSquare Capital LLC | 10,000 | $62.0K |
| Slow Capital, Inc. | 655 | $4.06K |